11 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
17 Dec 20
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
9:02am
and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
14 Jun 21
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
9:00am
majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions
8-K
ATXI
Avenue Therapeutics Inc
16 May 22
Entry into a Material Definitive Agreement
4:44pm
$7.5 million, (ii) the agreement by minority Avenue stockholder InvaGen Pharmaceuticals Inc. (“InvaGen”) to (A) have 100% of its shares in the Company
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
12 Mar 19
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
9:16am
at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership
8-K
EX-99.1
acrq9v1sp1yc37pf
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
- Prev
- 1
- Next